Definium Therapeutics (NASDAQ:DFTX) vs. Tetra Bio-Pharma (OTCMKTS:TBPMF) Critical Analysis

Definium Therapeutics (NASDAQ:DFTX) and Tetra Bio-Pharma (OTCMKTS:TBPMF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Insider & Institutional Ownership

27.9% of Definium Therapeutics shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Definium Therapeutics and Tetra Bio-Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$108.68 million	($2.04)	-8.09
Tetra Bio-Pharma	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Definium Therapeutics and Tetra Bio-Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1	0	8	3	3.08
Tetra Bio-Pharma	0	0	0	0	0.00

Definium Therapeutics presently has a consensus price target of $32.11, suggesting a potential upside of 94.49%. Given Definium Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Tetra Bio-Pharma.

Profitability

This table compares Definium Therapeutics and Tetra Bio-Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-86.18%	-62.29%
Tetra Bio-Pharma	N/A	N/A	N/A

Summary

Definium Therapeutics beats Tetra Bio-Pharma on 6 of the 8 factors compared between the two stocks.

About Definium Therapeutics

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About Tetra Bio-Pharma

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.